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Candidate biomarkers for
erythropoietin response in
end-stage renal disease
Anatole Besarab1 and Jerry Yee1
Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is
important clinically and economically. Escalation of dose may produce
harm. Post hoc analyses of clinical trials showed that responsiveness
could be predicted by hemoglobin response to a fixed dose escalation.
This maneuver requires weeks to months. The study by Merchant et al.
offers promise that peptidomic analyses of patient sera and mass
spectrometry can identify biomarkers of both responsiveness and
resistance to ESAs.
Kidney International (2011) 79, 488–490. doi:10.1038/ki.2010.479

The paper by Merchant et al.1 in this issue
of Kidney International is an important
approach to the issue of hyporesponsiveness to erythropoiesis-stimulating agents
(ESAs) when obvious causes are not
apparent. Their approach is identification
of biomarkers of ESA response in hemodialysis patients, using peptidomic
analyses of patient sera and mass spectrometry. The findings of these experiments are interesting and novel, marking
the discovery of serum peptides originating from the oncostatin M receptor and
cysteine/histidine-rich 1 proteins as candidate biomarkers of poor and good
response to ESA therapy, respectively.
Although the study was restricted to the
use of the first-generation ESA epoetin
alfa, the approach is likely to extend to
similar-class biosimilar and longer-acting
agents and may extend to newly developing hypoxia-inducible factor (HIF)acting agents.
It must be stressed that introduction of
ESAs produced substantial reductions in
the blood transfusion requirements of
patients suffering from chronic kidney
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disease (CKD). Thus, hyporesponsiveness
to ESAs is an important issue in the successful management of anemia in patients
with CKD, and hyporesponsiveness may
be transient or persistent. The two most
common reasons why patients become
relatively unresponsive to ESA therapy are
the development of true iron deficiency
(which occurs less frequently now as a
result of aggressive iron supplementation)
and the onset of an inflammatory state
that impairs the response to ESAs.2 These
elements are not unique to patients with
CKD, but patients with CKD, especially
those on hemodialysis, may be at an
increased risk due to inflammation and
may have previously been subject to
decreases in hemoglobin (Hb) and hematocrit and consequent increased ESA dose
requirements. Importantly, the bone
marrow progenitor cells that are the most
sensitive to the various cytokines produced during inflammation are the erythroid colony-forming units, as opposed to
the more primitive erythroid burst-forming units. The effects of some cytokines,
such as tumor necrosis factor-, are not
overcome by a simple increase in the ESA
concentrations.
Intercurrent infection is almost
certainly the most common reason why
patients become temporarily (and reversibly) ESA-resistant. ESA responsiveness

improves when iron deficiency (or another
substrate deficiency) or an underlying
inflammatory condition is treated.
Response to iron repletion is relatively
rapid, and very high Hb levels may obtain
when ESA doses are not down-titrated
rapidly. After therapy and control of the
inflammatory state, it may take weeks to
realize full responsiveness and several
months to attain the desired Hb level.
Reduction in cytokines, through prompt
treatment of the underlying disorder,
invariably engenders a much lower ESA
dose to achieve the target Hb level.
Entities that induce chronic ESA
hyporesponsiveness that can be partially
overcome by escalating ESA doses include
myelofibrosis, malignancy, thalassemia,
sickle-cell disease, and untreated HIV/
AIDS. The presence of these is usually
known at the time of anemia treatment
and ESA dose escalation. More recently
described is pure red-cell aplasia, which
results from antibodies directed against
endogenous and exogenous epoetins.
Until recently, the only available therapies
were immunosuppression and/or red
blood cell transfusions, but now administration of an erythromimetic peptide
without homology to erythropoietin has
been salutary.
It has been recognized since the initial
introduction of the first ESA, epoetin alfa,
in 1986–1987 that individual dialysisdependent CKD patients vary significantly
in the dose of ESA required to correct
their anemia. Many studies have shown
that the target mean Hb achieved is proportional to the dose given, at the population level. Data from the Clinical
Performance Measures Project of the
Centers for Medicare and Medicaid Services clearly demonstrate parallel increases
of Hb levels and epoetin doses from 1995
to 2004. As the dose increased from 175
U/kg to 275 U/kg weekly, the mean Hb
increased from 10.5 to 11.7 g/dl, while the
ESA dose of people who achieved an Hb
level of 11–13 g/dl varied more than
50-fold. The pressure to attain higher Hb
levels from 1997 to 2006 evolved in part
from perceived improvements in quality
of life and persistent observational findings of lower mortality and hospitalization
Kidney International (2011) 79
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Figure 1 | Data on epoetin alfa usage in the last quarter of 2005 in the United States, based
on a sample of 7400 patients. The percentage of total epoetin used according to percentile of
dose range is an exponential curve. Hyporesponsive patients ( > 150 U/kg of epoetin three times
weekly) are in the highest quintile of doses ( > 30,000 U/wk). Not surprisingly, they consume more
than half of all the epoetin used, yet their hemoglobin levels are never greater than those of the
patients in the lower quintiles. ESA, erythropoiesis-stimulating agent.

at higher as compared with lower achieved
Hb values in hemodialysis patients.
This upward trend in Hb levels ended
abruptly in 2006 with the publication of
the Cardiovascular Risk Reduction by
Early Anemia Treatment with Epoetin
Beta (CREATE) and Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trials in non-dialysis
CKD patients, and a meta-analysis in
dialysis-dependent and non-dialysis CKD
patients that targeted an entire population
to a Hb level of at least 13 g/dl produced
harm rather than further benefit, 3
confirming the original observation of the
Normal Hematocrit Trial (NHCT).4 These
recent clinical trials included dialysisdependent 5 and non-dialysis CKD
patients6 treated with ESAs to Hb targets
greater than the range labeled by the US
Food and Drug Administration, 10–12
g/dl, and raised safety concerns. Product
labeling was subsequently revised to
include a black-box warning, which, in
the United States, led to a reduction from
60% to 46% in the proportion of nondialysis CKD patients receiving an ESA, a
25% reduction in ESA dose and a decrease
from 11.5 g/dl to 10.6 g/dl in mean Hb
Kidney International (2011) 79

achieved.7 Notably, this trend had begun
before publication of the CHOIR trial in
2007 and accelerated thereafter. US Renal
Data System data depict a similar, less dramatic decrease in mean Hb (of 0.5 g/dl)
and in ESA dose in dialysis-dependent
CKD patients (A.J. Collins, personal communication).
The paradox of observational trials
demonstrating benefit and randomized
controlled trials revealing harm at higher
achieved Hb levels may arise from the
administration of futile higher ESA doses
to relatively ESA-resistant CKD patients.
In an analysis of data from 7400 randomly
selected patients representing the US
hemodialysis population in 2005 (the
Clinical Performance Measures Project),
we found that 15% of hyporesponsive
patients (defined as > 150 U/kg of epoetin
alfa administered three times weekly)
consumed 52.5% of the total ESAs prescribed (Figure 1). In many, ESA dose
escalations did not alter Hb over a
3-month period. Consequently, we proposed a hypothesis based on post hoc
analyses of the NHCT8 and the CHOIR
trial:9 failure to achieve high Hb levels,
rather than the level itself, may have been

responsible for the poor outcomes. Similarly, the Trial to Reduce Cardiovascular
Events With Aranesp Therapy (TREAT)
post hoc analysis by Solomon and colleagues10 correlated an initial suboptimal
response with enhanced risk for a cardiovascular composite event (hazard ratio
1.31) and for all-cause death (hazard ratio
1.41). The poor outcomes may have
resulted from toxicities related to highdose ESAs, patient-level factors underpinning ESA hyporesponsiveness, or a
combination of both. The CREATE trial
did not demonstrate any harm from the
greater targeted Hb, but the median
epoetin doses were considerably lower
(5000 IU/wk and 2000 IU/wk in the normal and subnormal Hb groups, respectively) than those in the NHCT and
CHOIR studies, suggesting that a high Hb
target per se may not have been directly
responsible for worse outcomes when
high doses of ESAs were avoided.
Currently, there is reasonable evidence
to indicate possibly more harm than benefit from targeting higher Hb levels with
ESA therapy, especially in hyporesponsive
people. Clinical trials to date have focused
primarily on Hb targets and have
neglected ESA dosing and other patientrelated factors, including concurrent illness, inflammation, and iron therapy. We
contend that a two-by-two factorial trial
of the hyporesponsive patient should be
conducted. Eligible patients would be randomized to a higher or lower ESA dose and
a higher or lower Hb target within the currently recommended range, 10–12 g/dl.
Unfortunately, until the study by
Merchant et al.,1 there has been disagreement on a uniform definition of hyporesponsiveness. Assigning responsiveness
from a snapshot of data over 1 or 2 months
could easily produce misclassification,
particularly in ESA-naive patients. Transient cycling within a 6-month period is
well established, and during the cycle, Hb
may vary by 2–4 g/dl while ESA doses are
varied monthly (or more frequently) in an
attempt to avoid Hb levels outside the
range, usually with a pronounced lag
phase between the ESA change and the
resulting Hb level.
A major strength of the study by
Merchant et al.1 is that an observation
period of 6 months was used to determine
489
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patients’ ESA response index and the division of responses into quintiles. This
avoided inclusion of transiently hyporesponsive patients based on conditions
not immediately apparent to the clinician.
Our own experience suggests that a period
of 6 months is needed to detect hyporesponsiveness in about 15% of the hemodialysis population, who remain
hyporesponsive for that duration. Their
dose of ESA is markedly higher than that
of sensitive patients, but because of the
constraints of the ‘target’ range, the same
mean Hb is attained. The importance of
detecting this subset resides in the economic cost of ESA therapy (Figure 1) and
in opportunities to avoid harm from
“excessive” ESA dosing to reach the
desired Hb target.
As important as economics is, the issue
of risk versus benefit when higher Hb
levels are targeted may be more important. If the findings of an association
between the relative abundance of oncostatin M fragments and poor response,
and between cysteine/histidine-rich 1 and
good response, can be confirmed in larger
cohorts of patients, it may allow us to
actually conduct the randomized controlled trials necessary to find the best strategy for managing such poorly responsive
patients. Certainly, this strategy cannot be
to increase the ESA dose until the same
Hb level is reached in poor as in better
responders—that is, equivalent Hb attainment in all quartiles or quintiles of dose.
The ability to periodically determine the
responsiveness of the patient can only help
refine the use and prevent the misuse of
ESAs.
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Prevention of vascular
calcification: is pyrophosphate
therapy a solution?
Veerle P. Persy1 and Marc D. McKee2,3
Pyrophosphate, a ubiquitous small-molecule inhibitor of mineralization
abundantly present in the extracellular environment, binds to calcium
and mineral surfaces to inhibit crystal growth. O’Neill and colleagues
show in uremic rats that systemic administration of pyrophosphate
prevents or reduces uremia-related vascular calcification, without overt
negative consequences for bone and without calcium pyrophosphate
deposition disease. These findings prompt further research into the
potential of pyrophosphate as treatment for vascular calcification in
chronic kidney disease patients.
Kidney International (2011) 79, 490–493. doi:10.1038/ki.2010.478

Chronic kidney disease (CKD) strongly
increases patient risk for cardiovascular
morbidity and mortality. This striking difference in cardiovascular risk between
CKD patients and the general population
is not attributable only to increased exposure to the traditional Framingham Study
risk factors but in addition depends on a
number of so-called ‘novel,’ uremiarelated risk factors, among which miner1Hugin Mugin Research, Antwerp, Belgium;
2Faculty of Dentistry, McGill University, Montreal,

Quebec, Canada and 3Department of Anatomy
and Cell Biology, McGill University, Montreal,
Quebec, Canada.
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alization of blood vessels (vascular
calcification, an ectopic mineralization)
takes a prominent position.1
Numerous epidemiologic studies have
found that vascular calcification in CKD
patients contributes to the increased
cardiovascular risk in this population,
and that hyperphosphatemia and hypercalcemic episodes are associated with
the development of uremia-related vascular calcification. The intimate link
between disturbances of mineral metabolism inherent to impaired renal
function and the development of both
renal osteodystrophy and vascular calcification is now broadly captured under
the term ‘chronic kidney disease –
mineral and bone disorder.’2
Kidney International (2011) 79

